Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens

Effective Cancer Vaccine Platform Based on AttenuatedSalmonellaand a Type III Secretion System

“…To comprehensively evaluate the potential of genes of the SsrAB virulon of S. typhimurium, we compared their promoter and effector activities to express and translocate heterologous proteins for antigen presentation. The results from these studies are summarized in two recent publications from our labs (8;17). Based on these results, we selected the four strongest in vivo -induced promoters ( P sifB , P sseJ , P sifA and P sseA ) (8) and tested combinations thereof with five genes sseJ , sifA , steC , sseL , and sseF encoding translocated effector proteins (17) using OVA as a model antigen in an in vitro antigen-presentation assay.…”

“…The results from these studies are summarized in two recent publications from our labs (8;17). Based on these results, we selected the four strongest in vivo -induced promoters ( P sifB , P sseJ , P sifA and P sseA ) (8) and tested combinations thereof with five genes sseJ , sifA , steC , sseL , and sseF encoding translocated effector proteins (17) using OVA as a model antigen in an in vitro antigen-presentation assay. We selected the effector proteins SseJ, SifA, SteC and SseL for comparison to the previously used effector protein SseF since these proteins show a characteristic association with endosomal membranes of the host cell after translocation, long half-life and high amounts of translocated fusion proteins (17).…”

Impact ofSalmonella entericaType III Secretion System Effectors on the Eukaryotic Host Cell

“…T3SSs from several bacteria have already been used to export recombinant proteins including enzymes, peptides to induce an immune response, and spider silk proteins, but the range of foreign proteins that can be secreted and their limits are currently under study [161]. Effectors are also promising candidates to be carriers for delivery of heterologous vaccine antigens, especially T3SS2 effectors that are synthesized only when Salmonella is inside host cells [162].…”

dbDiarrhea: The database of pathogen proteins and vaccine antigens from diarrheal pathogens

“…T3SS is a common stratagem deployed by several enteric bacteria to translocate toxins and effector proteins across the host cell via an injectisome and subvert normal cell functions to aid infections (Cornelis, 2006). In another illuminating investigation, T3SS effectors have demonstrated promise as broadly cross-protective vaccine candidates (Martinez-Becerra et al, 2012) as well as carriers of vaccine antigens (Hegazy et al, 2012). Few reports have also indicated that T3SS inhibitors have the potential to be developed into novel antibacterial therapeutics (Kline et al, 2009(Kline et al, ,2012.…”